Health Canada clears Moderna Phase 1 trial for Bundibugyo Ebola vaccine mRNA-1469

PUBT · 1d ago
Health Canada clears Moderna Phase 1 trial for Bundibugyo Ebola vaccine mRNA-1469
  • Health Canada cleared Moderna’s Phase 1 trial of mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus.
  • CEPI committed up to USD 50 million to support preclinical work, the Phase 1 study, and scaled manufacturing of additional doses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608041100ACCESSWRNAPR_____1200749) on August 04, 2026, and is solely responsible for the information contained therein.